리펠라 파마슈티컬스(LIPO)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $0.00 (+0.00%), 시가총액 $0.00B, 52주 범위 $0.02 ~ $3.09.
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It develops LP-10, a formulation of tacrolimus for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; LP-410, an oral liposomal formulation of tacrolimus to treat oral graft-versus-host disease; and LP-50, an intravesical formulation of immunoglobulins for the treatment of non-muscle invasive bladder cancer. Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh,
리펠라 파마슈티컬스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
리펠라 파마슈티컬스의 현재 주가는 $0.00 (+0.00%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
리펠라 파마슈티컬스의 시가총액은 약 $0.00B입니다.
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for v